MGEN - シグナル・ジェネティクス (Miragen Therapeutics Inc.)

MGENのニュース

   AMD, SWIR among premarket gainers  2020/07/24 12:24:43 Seeking Alpha
Natuzzi NTZ +131% on renewing its securitization facility. Miragen Therapeutics MGEN +45% on Orphan Drug tag for Cobomarsen in blood cancer. Theratechnolog
   Miragen Therapeutics : KOL Call on MRG-229 for the Treatment of Idiopathic Pulmonary Fibrosis | MarketScreener  2020/06/25 14:19:05 MarketScreener
Restoring Biological Harmony for Patients with Debilitating Disease KOL Call on MRG-229 for the Treatment of Idiopathic Pulmonary Fibrosis … | June 25, 2020
   Thinking about buying stock in Energous Corp, Miragen Therapeutics, Hertz, Kopin Corp, or MGM Resorts?  2020/06/17 13:31:00 PR Newswire
NEW YORK, June 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WATT, MGEN, HTZ, KOPN, and MGM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Has Signal Genetics (MGEN) Outpaced Other Medical Stocks This Year?  2020/02/14 16:30:11 Zacks Investment Research
Is (MGEN) Outperforming Other Medical Stocks This Year?
   Adult T-Cell Leukemia-Lymphoma Pipeline Insight, 2020 Featuring Daiichi Sankyo, Seattle Genetics, miRagen Therapeutics, and Celgene Corp  2020/02/03 17:30:00 Benzinga Feeds
DUBLIN , Feb. 3, 2020 /PRNewswire/ -- The "Adult T-Cell Leukemia-Lymphoma - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Adult T-Cell Leukemia-Lymphoma Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the adult t-cell leukemia-lymphoma market. A detailed picture of the adult t-cell leukemia-lymphoma pipeline landscape is provided, which includes the disease overview and adult t-cell leukemia-lymphoma treatment guidelines. The assessment part of the report embraces in-depth adult t-cell leukemia-lymphoma commercial assessment and clinical assessment of the adult t-cell leukemia-lymphoma pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, adult t-cell leukemia-lymphoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
   AMD, SWIR among premarket gainers  2020/07/24 12:24:43 Seeking Alpha
Natuzzi NTZ +131% on renewing its securitization facility. Miragen Therapeutics MGEN +45% on Orphan Drug tag for Cobomarsen in blood cancer. Theratechnolog
   Miragen Therapeutics : KOL Call on MRG-229 for the Treatment of Idiopathic Pulmonary Fibrosis | MarketScreener  2020/06/25 14:19:05 MarketScreener
Restoring Biological Harmony for Patients with Debilitating Disease KOL Call on MRG-229 for the Treatment of Idiopathic Pulmonary Fibrosis … | June 25, 2020
   Thinking about buying stock in Energous Corp, Miragen Therapeutics, Hertz, Kopin Corp, or MGM Resorts?  2020/06/17 13:31:00 PR Newswire
NEW YORK, June 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WATT, MGEN, HTZ, KOPN, and MGM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Has Signal Genetics (MGEN) Outpaced Other Medical Stocks This Year?  2020/02/14 16:30:11 Zacks Investment Research
Is (MGEN) Outperforming Other Medical Stocks This Year?
   Adult T-Cell Leukemia-Lymphoma Pipeline Insight, 2020 Featuring Daiichi Sankyo, Seattle Genetics, miRagen Therapeutics, and Celgene Corp  2020/02/03 17:30:00 Benzinga Feeds
DUBLIN , Feb. 3, 2020 /PRNewswire/ -- The "Adult T-Cell Leukemia-Lymphoma - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Adult T-Cell Leukemia-Lymphoma Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the adult t-cell leukemia-lymphoma market. A detailed picture of the adult t-cell leukemia-lymphoma pipeline landscape is provided, which includes the disease overview and adult t-cell leukemia-lymphoma treatment guidelines. The assessment part of the report embraces in-depth adult t-cell leukemia-lymphoma commercial assessment and clinical assessment of the adult t-cell leukemia-lymphoma pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, adult t-cell leukemia-lymphoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
   AMD, SWIR among premarket gainers  2020/07/24 12:24:43 Seeking Alpha
Natuzzi NTZ +131% on renewing its securitization facility. Miragen Therapeutics MGEN +45% on Orphan Drug tag for Cobomarsen in blood cancer. Theratechnolog
   Miragen Therapeutics : KOL Call on MRG-229 for the Treatment of Idiopathic Pulmonary Fibrosis | MarketScreener  2020/06/25 14:19:05 MarketScreener
Restoring Biological Harmony for Patients with Debilitating Disease KOL Call on MRG-229 for the Treatment of Idiopathic Pulmonary Fibrosis … | June 25, 2020
   Thinking about buying stock in Energous Corp, Miragen Therapeutics, Hertz, Kopin Corp, or MGM Resorts?  2020/06/17 13:31:00 PR Newswire
NEW YORK, June 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WATT, MGEN, HTZ, KOPN, and MGM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Has Signal Genetics (MGEN) Outpaced Other Medical Stocks This Year?  2020/02/14 16:30:11 Zacks Investment Research
Is (MGEN) Outperforming Other Medical Stocks This Year?
   Adult T-Cell Leukemia-Lymphoma Pipeline Insight, 2020 Featuring Daiichi Sankyo, Seattle Genetics, miRagen Therapeutics, and Celgene Corp  2020/02/03 17:30:00 Benzinga Feeds
DUBLIN , Feb. 3, 2020 /PRNewswire/ -- The "Adult T-Cell Leukemia-Lymphoma - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Adult T-Cell Leukemia-Lymphoma Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the adult t-cell leukemia-lymphoma market. A detailed picture of the adult t-cell leukemia-lymphoma pipeline landscape is provided, which includes the disease overview and adult t-cell leukemia-lymphoma treatment guidelines. The assessment part of the report embraces in-depth adult t-cell leukemia-lymphoma commercial assessment and clinical assessment of the adult t-cell leukemia-lymphoma pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, adult t-cell leukemia-lymphoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

calendar